Lymphatic Filariasis (LF) in Ivory Coast

NACompletedINTERVENTIONAL
Enrollment

189

Participants

Timeline

Start Date

January 31, 2015

Primary Completion Date

September 30, 2018

Study Completion Date

September 25, 2018

Conditions
Lymphatic Filariasis
Interventions
DRUG

Albendazole

"Subjects in Arms 1, 2, and 4 will receive 400mg of Albendazole~Subjects in Arm 3 will receive 800mg of Albendazole"

DRUG

Ivermectin

Subjects in Arms 1 and 4 will receive 200mg/kg body weight

DRUG

Diethylcarbamazine

Participants in Arm 4 will receive 6mg/kg of Diethylcarbamazine per body weight

Trial Locations (1)

Unknown

Cote d'Ivoire, Abidjan

All Listed Sponsors
collaborator

Washington University School of Medicine

OTHER

lead

University Hospitals Cleveland Medical Center

OTHER

NCT02974049 - Lymphatic Filariasis (LF) in Ivory Coast | Biotech Hunter | Biotech Hunter